Does TRICARE Cover Trazodone? Formulary Tier, Prior Authorization, and Appeal Steps

TRICARE Formulary Placement for Trazodone

Trazodone is classified as a preferred generic on the TRICARE Uniform Formulary, which means it carries the lowest out-of-pocket cost across all TRICARE plan types. The Department of Defense Pharmacy and Therapeutics Committee reviews formulary placement annually, and trazodone has maintained preferred status for over a decade due to its low cost, established safety record, and broad clinical utility [1].

What "Preferred Generic" Means for Your Copay

TRICARE uses a three-tier structure: generic formulary, brand-name formulary, and non-formulary. Trazodone falls into the first tier. At military treatment facility (MTF) pharmacies, the copay is $0. Through TRICARE retail network pharmacies, TRICARE Prime beneficiaries pay $14 for a 30-day fill. TRICARE Select beneficiaries pay the same $14 copay after meeting their annual deductible.

Home Delivery Option

The TRICARE home delivery program, managed by Express Scripts, offers a 90-day supply of trazodone for $0. This is often the most cost-effective route for beneficiaries on maintenance therapy. Prescriptions can be transferred to home delivery through the Express Scripts portal or by calling the TRICARE pharmacy help line.

For comparison, the average retail cash price for trazodone 50 mg (30 tablets) runs about $10 per month at commercial pharmacies, according to GoodRx pricing data. TRICARE's $0 MTF and $0 home delivery options make insurance coverage the clear better deal, even against already-low generic prices.

Prior Authorization: When It Applies and When It Does Not

For the vast majority of trazodone prescriptions, TRICARE does not require prior authorization. Standard prescribing for major depressive disorder (the FDA-approved indication) and low-dose off-label use for insomnia both process through pharmacy claims without additional review [2].

Scenarios That Could Trigger a Review

Prior authorization may be flagged in a small number of cases. These include unusually high daily doses (above 400 mg per day for outpatient use), combination regimens where trazodone is prescribed alongside multiple other serotonergic agents, or requests that fall outside typical clinical patterns. The TRICARE claims system uses automated utilization management edits. If a prescription triggers an edit, the dispensing pharmacy receives a rejection code, and the prescribing provider must submit clinical justification.

How Providers Submit Authorization

When authorization is required, the prescriber contacts the TRICARE regional contractor (East Region: Humana Military; West Region: Health Net Federal Services). The process involves submitting a completed Prior Authorization Request Form along with chart notes supporting the clinical rationale. Typical turnaround time is 5 business days for non-urgent requests and 72 hours for urgent requests.

The Mendelson 2005 review in the Journal of Clinical Psychiatry documented trazodone's efficacy for insomnia at doses of 25 to 150 mg, providing a well-cited reference that clinicians can use to support off-label authorization requests if needed [3].

Step Therapy Requirements

TRICARE does not impose step therapy for trazodone. There is no requirement to try and fail another antidepressant or sleep medication before a provider can prescribe trazodone. This distinguishes trazodone from some newer branded sleep agents (like suvorexant or lemborexant), which may carry step therapy or non-formulary restrictions under TRICARE.

Why Trazodone Avoids Step Therapy

Step therapy policies target high-cost medications where less expensive alternatives exist. Trazodone is already among the lowest-cost options in both the antidepressant and sleep medication categories. Its generic availability since 1981, combined with decades of clinical use data, means TRICARE has no cost or safety rationale to restrict first-line access [1].

Switching From Another Medication

If a beneficiary is currently taking a different antidepressant or sleep medication and wants to switch to trazodone, no prior authorization barrier exists. The prescribing clinician simply writes the new prescription. Cross-titration schedules vary depending on the medication being discontinued. For patients switching from an SSRI to trazodone for combined antidepressant and sleep benefit, many clinicians add low-dose trazodone (50 mg at bedtime) while continuing the existing SSRI rather than switching outright [4].

Off-Label Insomnia Use Under TRICARE

Trazodone's most common real-world application is off-label insomnia treatment at low doses (25 to 100 mg at bedtime). A 2017 analysis published in the Journal of Clinical Sleep Medicine found that trazodone was the most frequently prescribed medication for insomnia in the United States, prescribed more often for sleep than for its FDA-approved depression indication [5].

Clinical Evidence for Insomnia

The evidence base for trazodone in insomnia is moderate. Mendelson's 2005 review identified consistent short-term improvements in sleep latency and sleep maintenance at doses of 50 to 100 mg [3]. A randomized controlled trial by Walsh et al. (1998) in 306 patients with primary insomnia demonstrated that trazodone 50 mg reduced subjective sleep latency by approximately 10 minutes compared to placebo over a 2-week period, though effects diminished by week 2 of continuous use [6].

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline gives a conditional recommendation against trazodone for chronic insomnia due to limited long-term data, while acknowledging that individual patient factors may justify its use [7]. TRICARE covers trazodone for insomnia despite this guideline position because the formulary covers the drug itself, not specific indications.

Dose Ranges and Monitoring

For insomnia, most clinicians prescribe between 25 mg and 100 mg at bedtime. The depression dose range is higher: 150 mg to 400 mg daily in divided doses, with a maximum of 600 mg per day in hospitalized patients, per the FDA-approved labeling [2]. TRICARE covers the full dose range without quantity limits on standard tablet strengths (50 mg, 100 mg, 150 mg, 300 mg).

How to Appeal a TRICARE Trazodone Denial

Denials for trazodone are uncommon but can happen. The most typical reasons include dosage limit flags, duplicate therapy edits (if another serotonergic drug is already on file), or enrollment verification issues.

Step-by-Step Appeal Process

The TRICARE appeal process follows a structured three-level pathway.

First level: Reconsideration. Submit a written request to the TRICARE regional contractor within 90 days of the denial. Include the Explanation of Benefits (EOB) showing the denial, a letter from the prescribing physician with clinical justification, and any supporting medical records. Mail or fax to the address on the EOB.

Second level: Formal appeal. If reconsideration is denied, file a formal appeal within 60 days. This goes to the same regional contractor but receives review by a different clinical team. Include any additional evidence, published clinical guidelines, or specialist consultation notes.

Third level: Independent external review. If the formal appeal fails, request an independent hearing. For TRICARE Prime, this is handled through the TRICARE Hearing Office. For TRICARE Select, the Defense Health Agency contracts with an independent review organization. This final level produces a binding decision.

Timeline Expectations

First-level reconsideration decisions typically arrive within 30 calendar days. Formal appeals take up to 60 days. External review can extend to 90 days. For urgent clinical situations (for example, a patient in acute depressive crisis whose only tolerated medication is trazodone), providers can request an expedited review with a 72-hour turnaround.

Strengthening Your Appeal

The strongest appeals combine three elements: a provider letter documenting treatment history and rationale, published evidence supporting the specific use case, and documentation of adverse effects or treatment failure with formulary alternatives. For trazodone appeals specifically, citing the medication's preferred formulary status and its decades-long safety profile usually resolves the issue at the first level.

TRICARE Plan Variations

TRICARE operates several distinct plans, and trazodone coverage details vary slightly across them.

TRICARE Prime and TRICARE Select

Both Prime and Select cover trazodone as a preferred generic. The difference is cost structure. Prime has fixed copays ($0 MTF, $14 retail, $0 home delivery). Select requires meeting a yearly deductible ($176 individual / $352 family for E-5 and above; lower for junior enlisted) before the $14 copay applies.

TRICARE For Life

Beneficiaries with TRICARE For Life (the supplement for Medicare-eligible retirees) have trazodone covered under Medicare Part D first, with TRICARE For Life picking up remaining costs. In practice, most Part D plans cover generic trazodone at Tier 1, resulting in copays of $0 to $5. TRICARE For Life then covers any residual balance.

TRICARE Reserve Select and Retired Reserve

These plans follow the same formulary as TRICARE Select, with identical copay tiers. Trazodone remains a preferred generic with the same cost-sharing structure.

Manufacturer Savings Cards and TRICARE

Federal law prohibits the use of manufacturer copay cards, coupons, or savings programs with any government-funded insurance, including TRICARE. This restriction applies under the Anti-Kickback Statute (42 U.S.C. § 1320a-7b). Even if a trazodone manufacturer offered a savings card, TRICARE beneficiaries could not legally apply it to their prescription costs [8].

This restriction is largely academic for trazodone. With copays ranging from $0 to $14 and no branded version currently marketed, there are no manufacturer savings programs to speak of. The restriction becomes more relevant for beneficiaries taking branded medications where copay cards could otherwise offset significant out-of-pocket costs.

Trazodone Safety Profile: What TRICARE Beneficiaries Should Know

Trazodone carries an FDA black box warning for suicidality risk in children, adolescents, and young adults (under age 25) during the initial weeks of antidepressant treatment [2]. This warning applies to all antidepressants and does not affect TRICARE coverage or formulary status.

Common Side Effects

The most frequently reported side effects in clinical trials include drowsiness (affecting roughly 20 to 30% of patients at antidepressant doses), dizziness (approximately 20%), dry mouth (15 to 25%), and nausea (10 to 15%) [2]. At the lower doses used for insomnia, drowsiness is the intended effect rather than a side effect, and other adverse effects occur less frequently.

Priapism Risk

Trazodone carries a rare but clinically significant risk of priapism (prolonged, painful erection). The estimated incidence is between 1 in 6,000 and 1 in 8,000 male patients [9]. This risk requires patient counseling at the time of prescribing. Priapism is a urological emergency that can cause permanent erectile damage if untreated beyond 4 hours. TRICARE covers emergency department visits for priapism under standard emergency care benefits.

Drug Interactions

Trazodone is metabolized by CYP3A4. Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) can increase trazodone plasma levels substantially. The FDA label recommends dose reduction when trazodone is co-administered with strong CYP3A4 inhibitors [2]. Combination with MAOIs is contraindicated due to serotonin syndrome risk. These interaction considerations do not change TRICARE coverage but may prompt automated drug utilization review flags at the pharmacy.

Comparing Trazodone to Other TRICARE-Covered Sleep and Depression Options

TRICARE covers a range of antidepressants and sleep medications. Understanding where trazodone fits helps beneficiaries and their providers make informed choices.

Versus SSRIs for Depression

SSRIs (sertraline, fluoxetine, escitalopram) are first-line for most depressive disorders per APA guidelines. Trazodone is typically used as an adjunct for patients whose SSRI causes insomnia, or as monotherapy for patients who cannot tolerate SSRIs. All major generic SSRIs sit on the same preferred generic tier as trazodone under TRICARE, with identical copays [1].

Versus Other Sleep Medications

Zolpidem (generic Ambien) is also a TRICARE preferred generic with comparable copays. Suvorexant (Belsomra) and lemborexant (Dayvigo) are branded agents that may require higher copays or prior authorization. Trazodone's advantage is its dual antidepressant-sleep utility, its lack of DEA scheduling (unlike zolpidem, which is Schedule IV), and its negligible abuse potential [5].

A 2014 systematic review by Everitt et al. In the Cochrane Database found limited high-quality evidence comparing trazodone directly to other hypnotics, noting that most trazodone-for-insomnia data comes from short-term trials with small sample sizes [10]. Despite this evidence gap, real-world prescribing patterns reflect provider confidence in trazodone's safety and tolerability profile for sleep.